Table 1.

CH defined by both acquired mCA and/or driver somatic mutations.

Participants	Discovery cohort					Validation cohort					Total
	Males		Female		Total	Males		Females		Total
	N	%	N	%		N	%	N	%
Total number	45,198	45	55,118	55	100,316	44,956	45	55,359	55	100,315	200,631
All CH	1286	45	1582	55	2868	1335	47	1515	53	2850	5718
Myeloid CHa	831	46	960	54	1791	885	49	912	51	1797	3588
Lymphoid CHb	135	48	146	52	281	140	46	167	54	307	588
All mCA	431	42	585	58	1016	439	44	561	56	1000	2016
Myeloid mCA	48	53	42	47	90	54	57	41	43	95	185
Lymphoid mCA	57	50	56	50	113	60	48	64	52	124	237
Other mCA	326	40	487	60	813	325	42	456	58	781	1594
All driver mutations	894	47	1027	53	1921	941	48	1001	52	1942	3863
Myeloid genesc,d	805	46	933	54	1738	854	49	890	51	1744	3482
DNMT3A	295	39	470	61	765	348	45	419	55	767	1532
TET2	193	46	225	54	418	188	46	217	54	405	823
ASXL1	103	64	59	36	162	92	64	51	36	143	305
JAK2	37	58	27	42	64	46	57	35	43	81	145
Other myeloid genes	220	54	190	46	410	225	52	207	48	432	842
Lymphoid genes	89	49	94	51	183	87	44	111	56	198	381
Control (CH-free)	43,912	45	53,536	55	97,448	43,621	45	53,844	55	97,465	194,913

^a79 participants had both myeloid mutations and myeloid mCA.

^bLymphoid CH was defined by lymphoid mCA and/or lymphoid mutations, without myeloid mutations or myeloid mCA. 30 participants had both lymphoid mutations and lymphoid mCA.

^c14 participants had both myeloid and lymphoid mutations and were classed as myeloid.

^d218 participants had more than one myeloid gene mutation.